

April 18, 2007



## **Cryo-Cell Names Two Officers to Key Scientific, Marketing Positions**

### **Allickson, Doll Promotions Support Strategic Plans to Advance Company's Position as Industry Leader in Innovative Stem Cell Solutions**

OLDSMAR, Fla., April 18 /PRNewswire-FirstCall/ -- The board of Cryo-Cell International Inc. (OTC Bulletin Board: CCEL), one of the world's largest cord blood banks, has elected two executives to top corporate positions. Julie Allickson, Ph.D., has been promoted to Vice President, Laboratory Operations, Research and Development. Rob Doll has been promoted to Vice President, Corporate Marketing, Sales and Services.

Dr. Allickson, who was previously Technical Laboratory Director, will continue to oversee laboratory operations, ensuring the quality and safety of umbilical cord blood stored for Cryo-Cell's 135,000 clients worldwide. In addition, she will lead the company's expanding intellectual property (IP) initiatives and technology portfolio. Dr. Allickson has nearly 20 years of laboratory experience, including 16 years of experience in cellular therapy processing, and is a founding member of the International Society of Cellular Therapy. She joined Cryo-Cell in 2004. Dr. Allickson recently completed a Ph.D. in Health Sciences at Touro University International, writing her dissertation on placental stem cells.

Mr. Doll, whose previous title was Vice President, Professional Marketing and Sales, oversees all aspects of sales and marketing for Cryo-Cell, including sales and support, new product development and global affiliate relations. He brings 14 years of professional healthcare and consumer marketing experience to Cryo-Cell, including a number of senior positions in companies such as AmeriPath and Gambro that grew rapidly under his management. Before joining Cryo-Cell, Mr. Doll was Chief Operating Officer of NovaVision, Inc., where he played a key role in launching the device company's product at major institutions such as Johns Hopkins and Columbia University.

"Julie Allickson and Rob Doll bring formidable experience and leadership to enhance Cryo-Cell's long-term growth strategy," said Mercedes Walton, Chairman and Chief Executive Officer. "Julie's scientific expertise, including her extensive knowledge of stem cell technologies and emerging R&D, will enable her to take the lead in developing new, life-saving and life-enhancing services on the frontier of regenerative science. Rob's proven ability to build and develop entrepreneurial companies, along with his extensive experience in consumer and professional marketing in the healthcare industry will be invaluable as Cryo-Cell expands our core business and builds our product and service portfolio."

About Cryo-Cell International Inc.

Based in Oldsmar, Florida, with over 135,000 clients worldwide, Cryo-Cell is one of the

largest and most established family cord blood banks. ISO 9001:2000 certified and accredited by the AABB, Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol: CCEL. Expectant parents or healthcare professionals may call 1-800-STOR-CELL (1-800-786-7235) or visit <http://www.cryo-cell.com>.

## Forward-Looking Statement

Statements wherein the terms "believes", "intends", "projects" or "expects" as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the uncertainty of market acceptance of any potential service offerings relating to types of stem cells other than cord blood stem cells, given that such new stem cells have not yet been used in human therapies, and treatment applications using such stem cells are subject to further research; need to complete certain developments, including completion of clinical validation and testing for commercialization of the process and the Company's development of its final business and economic model in offering any such service; any adverse effect or limitations caused by recent increases in government regulation of stem cell storage facilities; any increased competition in our business; any decrease or slowdown in the number of people seeking to store umbilical cord blood stem cells or decrease in the number of people paying annual storage fees; any adverse impacts on our revenue or operating margins due to the costs associated with increased growth in our business, including the possibility of unanticipated costs relating to the operation of our new facility; any technological breakthrough or medical breakthrough that would render the Company's business of stem cell preservation obsolete; any material failure or malfunction in our storage facilities; any natural disaster such as a tornado, other disaster (fire) or act of terrorism that adversely affects stored specimens; the costs associated with defending or prosecuting litigation matters and any material adverse result from such matters; decreases in asset valuations; any continued negative effect from adverse publicity in the past year regarding the Company's business operations; any negative consequences resulting from deriving, shipping and storing specimens at a second location; and other risks and uncertainties. The foregoing list is not exhaustive, and the Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements. Readers should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-KSB, Quarterly Reports on Form 10-QSB and any Current Reports on Form 8-K filed by the Company.

Contact:  
Chris Goldrick  
312-240-2726  
[chris.goldrick@edelman.com](mailto:chris.goldrick@edelman.com)

SOURCE Cryo-Cell International Inc.